• 1
    Atherton JC. H. pylori virulence factors. Br Med Bull 1998; 54: 11520.
  • 2
    Somerville K, Faulkner G, Langman MJS. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986; 1: 46246.
  • 3
    Hawkey CJ. Non-steroidal anti-inflammatory drugs and ulcers: Facts and Figures multiply, but do they add up? Br Med J 1990; 308: 27884.
  • 4
    Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 78796.
  • 5
    Somerville KW, Faulkner G, Langman MJS. Risk factors for non-steroidal anti-inflammatory drug-associated upper gastrointestinal bleeding. Eur J Gastroenterol Hepatol 1992; 4: 6459.
  • 6
    Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 76972.
  • 7
    Langman MJS, Weedle J, Wainwright P, et al.Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 10758.
  • 8
    Hochhain P, Berkelmans I, Czerichow P, et al.Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case control study. Eur J Gastroenterol Hepatol 1995; 7: 41926.
  • 9
    Henry D, Lim LL, Garcia Rodriguez LA, et al.Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 1996; 312: 15636.
  • 10
    Weil J, Langman MJS, Wainwright P, et al.Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 2731.
  • 11
    Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160(14): 20939.
  • 12
    Cullen DJE, Hawkey GM, Greenwood DC, et al.Peptic ulcer bleeding: relative roles of Helicobacter pylori and non-steroidal and anti-inflammatory drugs. Gut 1997; 41: 45962.
  • 13
    Censini S, Lange C, Xiang Z, et al.CagA, a pathogenicity island of Helicobacter, encodes type 1-specific and disease associated virulence factors. Proc Natl Acad Sci 1996; 93: 1464853.
  • 14
    Wilcox MH, Dent THS, Hunter JO, et al.Accuracy of serology for the diagnosis of Helicobacter pylori infection – a comparison of eight kits. J Clin Pathol 1996; 49: 3736.
  • 15
    Atherton JC. Non-endoscopic tests in the diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 1120.
  • 16
    Blaser MJ, Perez-Perez GI, Kleanthous H, et al.Infection with Helicobacter pylori strains possessing CagA is associated with increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55: 21115.
  • 17
    Atherton JC, Tham KT, Peek RM, Cover TL, Blaser MJ. Density of Helicobacter pylori in vivo as assessed by quantitative culture and histology. J Infect Dis 1996; 174: 5526.
  • 18
    Hudson N, Balsitis M, Filipowicz F, Hawkey CJ. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34: 74851.
  • 19
    World Health Organisation Collaborating Centre for Drug Statistics Methodology. Guidelines for Defined Daily Doses. Oslo: World Health Organisation, 1991.
  • 20
    Sontag S, Graham DY, Belsito A, Weiss J, Farley A, et al.Cimetidine, cigarette smoking, and recurrence of duodenal ulcer. N Engl J Med 1984; 11: 65993.
  • 21
    Piper DW, Nasiry R, McIntosh J, Shy CM, Pierce J, Byth K. Smoking, alcohol, analgesics and chronic duodenal ulcer. A controlled study of habits before first symptoms and before diagnosis. Scand J Gastroenterol 1984; 19: 101521.
  • 22
    Borody TJ, George LL, Brandl S, Andrews P, Jankiewicz E, Ostapowicz N. Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication. Am J Gastroenterol 1992; 87: 13903.
  • 23
    Weil J, Colin-Jones D, Langman M, et al.Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 8279.
  • 24
    Slattery J, Warlow CP, Shorrock CJ, Langman MJS. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin – analysis of gastrointestinal bleeding during UK-TIA trial. Gut 1995; 37: 50911.
  • 25
    Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153: 166570.
  • 26
    Younossi ZM, Strum WB, Schatz RA, et al.Effects of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding. Dig Dis Sci 1997; 42: 7982.
  • 27
    Soll AH. Gastric, duodenal and stress ulcer. In: Sleisenger, M, Fordtran, J, eds. Gastrointestinal Disease, 5th edn. Philadelphia: WB Saunders, Year?: 580–679.
  • 28
    Sakaki N, Momma K, Egawa N, Tu Y, Kato H. Preliminary clinical study on gastric ulcer scars and ulcer relapses after Helicobacter pylori eradication therapy. J Clin Gastroenterol 1997; 25: S22934.
  • 29
    Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ. Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol 1995; 210: 914.
  • 30
    Leung WK, Sung JJ, Siu KL, Chan FK, Ling TK, Cheng AF. False-negative biopsy urease test in bleeding ulcers caused by the buffering effects of blood source. Am J Gastro 1998; 93: 19148.
    Direct Link:
  • 31
    Wang WM, Chen CY, Jan CM, et al.Long-term follow-up and serological study after triple therapy. Am J Gastroenterol 1994; 89: 17936.
  • 32
    Veenendaal RA, Pena AS, Meijer JL, et al.Long term serological surveillance after treatment of Helicobacter pylori infection. Gut 1991; 32: 12914.
  • 33
    Berkson J. Limitations of the application of 4-fold tables to hospital data. Biometric Bull 1946; 2: 4753.
  • 34
    Crabtree JE, Taylor JD, Wyatt JI, et al.Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration and gastric pathology. Lancet 1991; 338: 3325.
  • 35
    Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40: 297301.
  • 36
    Segal ED, Cha J, Lo J, Falkow S, Tompkins LS. Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci USA 1999; 96: 1455964.
  • 37
    Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999; 116: 13059.
  • 38
    Wu CY, Poon SK, Chen GH, et al.Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding. Scand J Gastroenterol 1999; 34: 234234.
  • 39
    Labenz J, Peitz U, Kohl H, et al.Helicobacter pylori increases the risk of peptic ulcer bleeding: a case-control study. Ital J Gastroenterol Hepatol 1999; 31: 1105.
  • 40
    Pilotto A, Leandro G, Di Mario F, et al. Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study. Dig Dis Sci 1997; 42: 586586.
  • 41
    Santolaria S, Lanas A, Benito R, et al.Helicobacter Pylori infection is a protective factor for bleeding gastric ulcers but is not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999; 13: 15118.DOI: 10.1046/j.1365-2036.1999.00631.x
  • 42
    Bianchi Porro G, Parente F, Imbesi V, et al.Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. Gut 1996; 39: 2222.
  • 43
    Hawkey CJ, Tulassay Z, Szczepanski L, et al.Helicobacter pylori eradication in patients taking non-steroidal, anti-inflammatory drugs: The HELP Nsaids Study. Lancet 1998; 352: 101621.
  • 44
    Yanaka A, Nakahara A, Tanaka N, et al.Eradication of Helicobacter pylori does not prevent ulcer relapse in patients with NSAIDs-induced gastric ulcer. Gastroenterology 1999; 116: A362A362 (Abstract).
  • 45
    Chan FKL, Chung SCS, Suen RN, et al.Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 13: 96773.
  • 46
    Koelz HR, Bolten W, Dragosics B, et al.Primary prophylaxis of NSAID-induced gastroduodenal ulcers and dyspepsia in H. pylori (HP)-positive patients: randomized, double-blind, placebo-controlled treatment of HP infection vs. omeprazole. Gastroenterol 2000; 118: A250A250(Abstract).
  • 47
    Chan FKL, To K-F, Wu JCY, et al.Does eradiation of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy reduce the long-term risk of ulcers? A double-blinded randomised trial. Gastroenterology 2001; 120: A143A143(Abstract).
  • 48
    Silverstein FE, Graham DY, Senior JR, et al.Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 2419.
  • 49
    Hirschowitz BI, Hawkey CJ. Questions regarding future research on aspirin and the gastrointestinal tract. Am J Med 2000; 110: 74S78S.
  • 50
    Silverstein FE, Gaich G, Goldstein JL, et al.Gastrointestinal toxicity with celecoxib versus non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomised controlled trial. J Am Med Assoc 2000; 284: 124755.
  • 51
    Bombardardier C, Laine L, Reicin A, et al.A double-blind comparison of Rofecoxib and Naproxen on the incidence of clinically important upper gastrointestinal events. The VIGOR Trial. N Engl J Med 2001; 343: 15208.